Adjuvant and salvage radiation therapy after prostatectomy

American society for radiation oncology/american urological association guidelines

Richard K Valicenti, Ian Thompson, Peter Albertsen, Brian J. Davis, S. Larry Goldenberg, J. Stuart Wolf, Oliver Sartor, Eric Klein, Carol Hahn, Jeff Michalski, Mack Roach, Martha M. Faraday

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Purpose The purpose of this guideline was to provide a clinical framework for the use of radiation therapy after radical prostatectomy as adjuvant or salvage therapy. Methods and Materials A systematic literature review using PubMed, Embase, and Cochrane database was conducted to identify peer-reviewed publications relevant to the use of radiation therapy after prostatectomy. The review yielded 294 articles; these publications were used to create the evidence-based guideline statements. Additional guidance is provided as Clinical Principles when insufficient evidence existed. Results Guideline statements are provided for patient counseling, use of radiation therapy in the adjuvant and salvage contexts, defining biochemical recurrence, and conducting a restaging evaluation. Conclusions Physicians should offer adjuvant radiation therapy to patients with adverse pathologic findings at prostatectomy (ie, seminal vesicle invastion, positive surgical margins, extraprostatic extension) and salvage radiation therapy to patients with prostate-specific antigen (PSA) or local recurrence after prostatectomy in whom there is no evidence of distant metastatic disease. The offer of radiation therapy should be made in the context of a thoughtful discussion of possible short- and long-term side effects of radiation therapy as well as the potential benefits of preventing recurrence. The decision to administer radiation therapy should be made by the patient and the multidisciplinary treatment team with full consideration of the patient's history, values, preferences, quality of life, and functional status. The American Society for Radiation Oncology and American Urological Association websites show this guideline in its entirety, including the full literature review.

Original languageEnglish (US)
Pages (from-to)822-828
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume86
Issue number5
DOIs
StatePublished - Aug 1 2013

Fingerprint

Salvage Therapy
Radiation Oncology
Prostatectomy
radiation therapy
Radiotherapy
Guidelines
radiation
Recurrence
Publications
websites
physicians
Seminal Vesicles
antigens
Prostate-Specific Antigen
PubMed
Counseling
margins
therapy
Quality of Life
histories

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Adjuvant and salvage radiation therapy after prostatectomy : American society for radiation oncology/american urological association guidelines. / Valicenti, Richard K; Thompson, Ian; Albertsen, Peter; Davis, Brian J.; Goldenberg, S. Larry; Wolf, J. Stuart; Sartor, Oliver; Klein, Eric; Hahn, Carol; Michalski, Jeff; Roach, Mack; Faraday, Martha M.

In: International Journal of Radiation Oncology Biology Physics, Vol. 86, No. 5, 01.08.2013, p. 822-828.

Research output: Contribution to journalArticle

Valicenti, RK, Thompson, I, Albertsen, P, Davis, BJ, Goldenberg, SL, Wolf, JS, Sartor, O, Klein, E, Hahn, C, Michalski, J, Roach, M & Faraday, MM 2013, 'Adjuvant and salvage radiation therapy after prostatectomy: American society for radiation oncology/american urological association guidelines', International Journal of Radiation Oncology Biology Physics, vol. 86, no. 5, pp. 822-828. https://doi.org/10.1016/j.ijrobp.2013.05.029
Valicenti, Richard K ; Thompson, Ian ; Albertsen, Peter ; Davis, Brian J. ; Goldenberg, S. Larry ; Wolf, J. Stuart ; Sartor, Oliver ; Klein, Eric ; Hahn, Carol ; Michalski, Jeff ; Roach, Mack ; Faraday, Martha M. / Adjuvant and salvage radiation therapy after prostatectomy : American society for radiation oncology/american urological association guidelines. In: International Journal of Radiation Oncology Biology Physics. 2013 ; Vol. 86, No. 5. pp. 822-828.
@article{1b85ddb18ee74c8e8a53e77a71266766,
title = "Adjuvant and salvage radiation therapy after prostatectomy: American society for radiation oncology/american urological association guidelines",
abstract = "Purpose The purpose of this guideline was to provide a clinical framework for the use of radiation therapy after radical prostatectomy as adjuvant or salvage therapy. Methods and Materials A systematic literature review using PubMed, Embase, and Cochrane database was conducted to identify peer-reviewed publications relevant to the use of radiation therapy after prostatectomy. The review yielded 294 articles; these publications were used to create the evidence-based guideline statements. Additional guidance is provided as Clinical Principles when insufficient evidence existed. Results Guideline statements are provided for patient counseling, use of radiation therapy in the adjuvant and salvage contexts, defining biochemical recurrence, and conducting a restaging evaluation. Conclusions Physicians should offer adjuvant radiation therapy to patients with adverse pathologic findings at prostatectomy (ie, seminal vesicle invastion, positive surgical margins, extraprostatic extension) and salvage radiation therapy to patients with prostate-specific antigen (PSA) or local recurrence after prostatectomy in whom there is no evidence of distant metastatic disease. The offer of radiation therapy should be made in the context of a thoughtful discussion of possible short- and long-term side effects of radiation therapy as well as the potential benefits of preventing recurrence. The decision to administer radiation therapy should be made by the patient and the multidisciplinary treatment team with full consideration of the patient's history, values, preferences, quality of life, and functional status. The American Society for Radiation Oncology and American Urological Association websites show this guideline in its entirety, including the full literature review.",
author = "Valicenti, {Richard K} and Ian Thompson and Peter Albertsen and Davis, {Brian J.} and Goldenberg, {S. Larry} and Wolf, {J. Stuart} and Oliver Sartor and Eric Klein and Carol Hahn and Jeff Michalski and Mack Roach and Faraday, {Martha M.}",
year = "2013",
month = "8",
day = "1",
doi = "10.1016/j.ijrobp.2013.05.029",
language = "English (US)",
volume = "86",
pages = "822--828",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Adjuvant and salvage radiation therapy after prostatectomy

T2 - American society for radiation oncology/american urological association guidelines

AU - Valicenti, Richard K

AU - Thompson, Ian

AU - Albertsen, Peter

AU - Davis, Brian J.

AU - Goldenberg, S. Larry

AU - Wolf, J. Stuart

AU - Sartor, Oliver

AU - Klein, Eric

AU - Hahn, Carol

AU - Michalski, Jeff

AU - Roach, Mack

AU - Faraday, Martha M.

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Purpose The purpose of this guideline was to provide a clinical framework for the use of radiation therapy after radical prostatectomy as adjuvant or salvage therapy. Methods and Materials A systematic literature review using PubMed, Embase, and Cochrane database was conducted to identify peer-reviewed publications relevant to the use of radiation therapy after prostatectomy. The review yielded 294 articles; these publications were used to create the evidence-based guideline statements. Additional guidance is provided as Clinical Principles when insufficient evidence existed. Results Guideline statements are provided for patient counseling, use of radiation therapy in the adjuvant and salvage contexts, defining biochemical recurrence, and conducting a restaging evaluation. Conclusions Physicians should offer adjuvant radiation therapy to patients with adverse pathologic findings at prostatectomy (ie, seminal vesicle invastion, positive surgical margins, extraprostatic extension) and salvage radiation therapy to patients with prostate-specific antigen (PSA) or local recurrence after prostatectomy in whom there is no evidence of distant metastatic disease. The offer of radiation therapy should be made in the context of a thoughtful discussion of possible short- and long-term side effects of radiation therapy as well as the potential benefits of preventing recurrence. The decision to administer radiation therapy should be made by the patient and the multidisciplinary treatment team with full consideration of the patient's history, values, preferences, quality of life, and functional status. The American Society for Radiation Oncology and American Urological Association websites show this guideline in its entirety, including the full literature review.

AB - Purpose The purpose of this guideline was to provide a clinical framework for the use of radiation therapy after radical prostatectomy as adjuvant or salvage therapy. Methods and Materials A systematic literature review using PubMed, Embase, and Cochrane database was conducted to identify peer-reviewed publications relevant to the use of radiation therapy after prostatectomy. The review yielded 294 articles; these publications were used to create the evidence-based guideline statements. Additional guidance is provided as Clinical Principles when insufficient evidence existed. Results Guideline statements are provided for patient counseling, use of radiation therapy in the adjuvant and salvage contexts, defining biochemical recurrence, and conducting a restaging evaluation. Conclusions Physicians should offer adjuvant radiation therapy to patients with adverse pathologic findings at prostatectomy (ie, seminal vesicle invastion, positive surgical margins, extraprostatic extension) and salvage radiation therapy to patients with prostate-specific antigen (PSA) or local recurrence after prostatectomy in whom there is no evidence of distant metastatic disease. The offer of radiation therapy should be made in the context of a thoughtful discussion of possible short- and long-term side effects of radiation therapy as well as the potential benefits of preventing recurrence. The decision to administer radiation therapy should be made by the patient and the multidisciplinary treatment team with full consideration of the patient's history, values, preferences, quality of life, and functional status. The American Society for Radiation Oncology and American Urological Association websites show this guideline in its entirety, including the full literature review.

UR - http://www.scopus.com/inward/record.url?scp=84880018909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880018909&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2013.05.029

DO - 10.1016/j.ijrobp.2013.05.029

M3 - Article

VL - 86

SP - 822

EP - 828

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -